Vaxxinova is excited to announce the successful acquisition of the Avishield® poultry vaccine range from Dechra and the Dechra poultry vaccine research and development team based in Zagreb, Croatia.
This acquisition marks a significant milestone in our growth, enabling us to:
- Offer a complete portfolio of live vaccines against Infectious Bronchitis (IB), Gumboro Disease (IBD) and Newcastle Disease (ND)
- Have direct access to the European poultry vaccines market and strengthen our presence in the international markets
- Continue the development of the corresponding R&D pipeline, by the Zagreb R&D team
Victor van Solinge, Chief Executive Officer of Vaxxinova, remarked “The addition of the Avishield® portfolio significantly strengthens our position in the poultry vaccine market and complements our existing VAXXON® range. We are excited to welcome the R&D team in Zagreb, whose expertise will be instrumental to further extend our portfolio. This acquisition underlines our long-term commitment to the poultry industry.”
Dechra and Vaxxinova agreed on a smooth transition period, securing business continuity.
We’re excited about the opportunities this brings to our partners, customers, and the broader animal health community.